Minyoung Youn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minyoung Youn has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- A. Boudard
CEA, Centre de Saclay, IRFU/Service de Physique Nucleaire, F-91191 Gif-sur-Yvette, France
1 shared publication A. Narla
Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, USA
1 shared publicationAarthi Jayanthan
Phoenix Molecular Designs, Vancouver, BC, Canada, San Diego, USA
1 shared publication- Ajay Sharma
Jasper Therapeutics Redwood City California USA
1 shared publication Alexander B. Kim
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, USA
1 shared publication- Allison Ji
Jasper Therapeutics Redwood City California USA
1 shared publication
Latest Publications
- Open Access
Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human‐Mouse KIT
- Top Cited PapersOpen Access
- 16 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
Myeloid malignancies are heterogenous disorders characterized by distinct molecular drivers but share convergence of oncogenic signaling pathways and propagation by ripe pro-inflammatory niches. Here, we establish a comprehensive transcriptional atlas across the spectrum of myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML) through RNA-sequencing of 158 primary samples encompassing CD34+ hematopoietic stem/progenitor cells and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant networks of PI3K/AKT/mTOR signalling and NFκB-mediated hyper-inflammation. Combining ATAC-Seq, CUT&Tag, RNA-seq, and CyTOF, we demonstrate that targeting of ribosomal protein S6 kinase A1 (RSK1) suppresses NFκB activation and diminishes pro-inflammatory mediators including tumor necrosis factor (TNF) associated with MPN disease severity and transformation. We further evaluate a therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, currently in Phase 2 development for breast cancer, for use in myeloid malignancies. Treatment with PMD-026 suppressed disease burden across seven syngeneic and patient-derived xenograft leukemia mouse models spanning the spectrum of driver and disease-modifying mutations. These findings uncover a therapeutic avenue for a conserved dependency across MPN and sAML.
- 16 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Top Cited PapersOpen AccessRSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
Myeloid malignancies are heterogenous disorders characterized by distinct molecular drivers but share convergence of oncogenic signaling pathways and propagation by ripe pro-inflammatory niches. Here, we establish a comprehensive transcriptional atlas across the spectrum of myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML) through RNA-sequencing of 158 primary samples encompassing CD34+ hematopoietic stem/progenitor cells and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant networks of PI3K/AKT/mTOR signalling and NFκB-mediated hyper-inflammation. Combining ATAC-Seq, CUT&Tag, RNA-seq, and CyTOF, we demonstrate that targeting of ribosomal protein S6 kinase A1 (RSK1) suppresses NFκB activation and diminishes pro-inflammatory mediators including tumor necrosis factor (TNF) associated with MPN disease severity and transformation. We further evaluate a therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, currently in Phase 2 development for breast cancer, for use in myeloid malignancies. Treatment with PMD-026 suppressed disease burden across seven syngeneic and patient-derived xenograft leukemia mouse models spanning the spectrum of driver and disease-modifying mutations. These findings uncover a therapeutic avenue for a conserved dependency across MPN and sAML.
- Open Access
- 3 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-17
Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase
Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency. DBA is characterized by anemia, congenital anomalies, and cancer predisposition. Treatment for DBA is associated with significant morbidity. Here, we report the identification of Nemo-like kinase (NLK) as a potential target for DBA therapy. To identify new DBA targets, we screen for small molecules that increase erythroid expansion in mouse models of DBA. This screen identified a compound that inhibits NLK. Chemical and genetic inhibition of NLK increases erythroid expansion in mouse and human progenitors, including bone marrow cells from DBA patients. In DBA models and patient samples, aberrant NLK activation is initiated at the Megakaryocyte/Erythroid Progenitor (MEP) stage of differentiation and is not observed in non-erythroid hematopoietic lineages or healthy erythroblasts. We propose that NLK mediates aberrant erythropoiesis in DBA and is a potential target for therapy.
- 3 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-17
Open AccessDiamond Blackfan anemia is mediated by hyperactive Nemo-like kinase
Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency. DBA is characterized by anemia, congenital anomalies, and cancer predisposition. Treatment for DBA is associated with significant morbidity. Here, we report the identification of Nemo-like kinase (NLK) as a potential target for DBA therapy. To identify new DBA targets, we screen for small molecules that increase erythroid expansion in mouse models of DBA. This screen identified a compound that inhibits NLK. Chemical and genetic inhibition of NLK increases erythroid expansion in mouse and human progenitors, including bone marrow cells from DBA patients. In DBA models and patient samples, aberrant NLK activation is initiated at the Megakaryocyte/Erythroid Progenitor (MEP) stage of differentiation and is not observed in non-erythroid hematopoietic lineages or healthy erythroblasts. We propose that NLK mediates aberrant erythropoiesis in DBA and is a potential target for therapy.
- Open Access
- 26 October 2011
- Published by Springer Nature in Nature
- Vol. 480 (7375) , 132
Erratum: DNA demethylation for hormone-induced transcriptional derepression
- 26 October 2011
- Published by Springer Nature in Nature
- Vol. 480 (7375) , 132
Open AccessErratum: DNA demethylation for hormone-induced transcriptional derepression
- 1 August 2001
- Published by Elsevier in Nuclear Physics A
- Vol. 691 (1-2) , 189-192
The π− mesonic decay rates on 12ΛC, 28ΛSi and ΛFe
- 1 August 2001
- Published by Elsevier in Nuclear Physics A
- Vol. 691 (1-2) , 189-192
The π− mesonic decay rates on 12ΛC, 28ΛSi and ΛFe
- 1 December 1994
- Published by American Physical Society (APS) in Physical Review C
- Vol. 50 (6) , 2687-2694
(d,2p)nreaction at 2 GeV deuteron energyThe (d,2p)n deuteron breakup reaction was measured at 2 GeV deuteron energy in a kinematically complete experiment. Fivefold differential cross sections are given in a wide range of kinematical variables and analyzed in terms of impulse approximation and NN rescattering. The deuteron momentum density was determined and deviations were found depending on the value of the four-momentum transfer ‖t‖ in the scattering process. At low ‖t‖ the momentum densities are in good agreement with the impulse approximation whereas large discrepancies were found above q≊200 MeV/c when the four-momentum transfer was large. Various possible origins of the anomalous behavior at high q values are discussed.- 1 December 1994
- Published by American Physical Society (APS) in Physical Review C
- Vol. 50 (6) , 2687-2694
(d,2p)nreaction at 2 GeV deuteron energyThe (d,2p)n deuteron breakup reaction was measured at 2 GeV deuteron energy in a kinematically complete experiment. Fivefold differential cross sections are given in a wide range of kinematical variables and analyzed in terms of impulse approximation and NN rescattering. The deuteron momentum density was determined and deviations were found depending on the value of the four-momentum transfer ‖t‖ in the scattering process. At low ‖t‖ the momentum densities are in good agreement with the impulse approximation whereas large discrepancies were found above q≊200 MeV/c when the four-momentum transfer was large. Various possible origins of the anomalous behavior at high q values are discussed.